{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:51:36Z","timestamp":1776091896358,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","radiographyonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiography"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.radi.2025.103103","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:58:05Z","timestamp":1754434685000},"page":"103103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S2","title":["Prostate cancer detection with [99mTc]Tc-HYNIC-iPSMA SPECT: The Australian experience"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6180-8586","authenticated-orcid":false,"given":"G.","family":"Currie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4567-7547","authenticated-orcid":false,"given":"P.","family":"Tually","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Groombridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Meadows","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tagore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-8766","authenticated-orcid":false,"given":"N.","family":"Lenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.radi.2025.103103_bib1","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1038\/s41598-022-06958-2","article-title":"Urban-rural prostate cancer disparities in a regional state of Australia","volume":"12","author":"Foley","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.radi.2025.103103_bib2","series-title":"Cancer data in Australia","year":"2024"},{"issue":"1","key":"10.1016\/j.radi.2025.103103_bib3","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1186\/s12889-023-16706-4","article-title":"Work-related experiences of prostate cancer survivors in Australia: a qualitative study","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Public Health"},{"issue":"6","key":"10.1016\/j.radi.2025.103103_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5694\/j.1326-5377.2011.tb02977.x","article-title":"Urban-rural differences in prostate cancer outcomes in Australia: what has changed?","volume":"194","author":"Baade","year":"2011","journal-title":"Med J Aust"},{"key":"10.1016\/j.radi.2025.103103_bib5","series-title":"Prostate cancer in Australia \u2013 what do the numbers tell Us?","year":"2022"},{"issue":"1","key":"10.1016\/j.radi.2025.103103_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40644-024-00693-9","article-title":"Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study","volume":"24","author":"Kolade","year":"2024","journal-title":"Cancer Imaging"},{"issue":"4","key":"10.1016\/j.radi.2025.103103_bib7","first-page":"555","article-title":"Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises","volume":"28","author":"Santoni","year":"2014","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.radi.2025.103103_bib8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Afshar-Oromieh","year":"2013","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.radi.2025.103103_bib9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcb.10661","article-title":"Correspondence re: Ghosh A and heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Cardillo","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.radi.2025.103103_bib10","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1158\/0008-5472.CAN-09-1682","article-title":"Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer","volume":"69","author":"Hillier","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.radi.2025.103103_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.radi.2025.103103_bib12","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1007\/s00259-015-3106-6","article-title":"PSMA PET\/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer","volume":"42","author":"Giesel","year":"2015","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.radi.2025.103103_bib13","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.radi.2025.103103_bib14","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radi.2025.103103_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27092617","article-title":"A review on the current state and future perspectives of [(99m)Tc]Tc-Housed PSMA-i in prostate cancer","volume":"27","author":"Brunello","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.radi.2025.103103_bib16","series-title":"The supply of medical isotopes: an economic diagnosis and possible solutions","year":"2019"},{"key":"10.1016\/j.radi.2025.103103_bib17","first-page":"1","article-title":"Direct comparison of (99m)Tc-PSMA SPECT\/CT and (68)Ga-PSMA PET\/CT in patients with prostate cancer","volume":"8","author":"Albalooshi","year":"2020","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"10.1016\/j.radi.2025.103103_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.nucmedbio.2017.01.010","article-title":"(99m)Tc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen","volume":"48","author":"Xu","year":"2017","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.radi.2025.103103_bib19","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1038\/s41598-020-61129-5","article-title":"Evaluation of radiation dosimetry of (99m)Tc-HYNIC-PSMA and imaging in prostate cancer","volume":"10","author":"Zhang","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.radi.2025.103103_bib20","first-page":"43","article-title":"Real world experience with [99mTc]Tc-HYNIC-iPSMA SPECT prostate cancer detection: interim results from the global NOBLE registry","volume":"8","author":"Tually","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radi.2025.103103_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.nucmedbio.2020.05.005","article-title":"Review on (99m)Tc radiopharmaceuticals with emphasis on new advancements","volume":"92","author":"Duatti","year":"2021","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.radi.2025.103103_bib22","article-title":"Diagnostic performance of 99mTc-HYNIC-PSMA SPECT\/CT for biochemically recurrent prostate cancer after radical prostatectomy","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.radi.2025.103103_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nucmedbio.2017.01.012","article-title":"Clinical translation of a PSMA inhibitor for (99m)Tc-based SPECT","volume":"48","author":"Ferro-Flores","year":"2017","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.radi.2025.103103_bib24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00259-020-04863-2","article-title":"(68)Ga-PSMA PET\/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study","volume":"48","author":"Zhang","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"5","key":"10.1016\/j.radi.2025.103103_bib25","first-page":"332","article-title":"Head to head comparison performance of 99mTc-EDDA\/HYNIC-iPSMA SPECT\/CT and 68Ga-PSMA-11 PET\/CT a prospective study in biochemical recurrence prostate cancer patients","volume":"8","author":"Garc\u00eda-P\u00e9rez","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radi.2025.103103_bib26","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.3390\/cancers15245824","article-title":"Diagnostic performance of 99mTc-iPSMA SPECT\/CT in the initial staging of patients with unfavorable Intermediate-, High-, and very high-risk prostate cancer: a comparative analysis with 18F-PSMA-1007 PET\/CT","volume":"15","author":"Vargas-Ahumada","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.radi.2025.103103_bib27","first-page":"4857","article-title":"Caring for someone with cancer in rural Australia","volume":"30","author":"Gunn","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.radi.2025.103103_bib28","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.22605\/RRH4019","article-title":"What does it cost to provide equity of access to high quality, comprehensive primary health care in rural Australia? A pilot study","volume":"17","author":"Thomas","year":"2017","journal-title":"Rural Remote Health"},{"key":"10.1016\/j.radi.2025.103103_bib29","doi-asserted-by":"crossref","DOI":"10.1053\/j.semnuclmed.2025.01.005","article-title":"Potential for technetium and rhenium theranostics","author":"Currie","year":"2025","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.radi.2025.103103_bib30","doi-asserted-by":"crossref","DOI":"10.1053\/j.semnuclmed.2025.01.007","article-title":"Sharpening the blade of precision theranostics","author":"Currie","year":"2025","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.radi.2025.103103_bib31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/pros.23444","article-title":"(99m) Tc-MIP-1404-SPECT\/CT for the detection of PSMA-Positive lesions in 225 patients with biochemical recurrence of prostate cancer","volume":"78","author":"Schmidkonz","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.radi.2025.103103_bib32","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2967\/jnumed.114.140426","article-title":"99mTc-labelled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer","volume":"55","author":"Vallabhajosula","year":"2014","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.radi.2025.103103_bib33","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s00259-020-04718-w","article-title":"Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET\/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy","volume":"47","author":"Miksch","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"5","key":"10.1016\/j.radi.2025.103103_bib34","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/MNM.0000000000001361","article-title":"Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-PSMA-11 PET\/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality","volume":"42","author":"Singh","year":"2021","journal-title":"Nucl Med Commun"},{"issue":"2","key":"10.1016\/j.radi.2025.103103_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","article-title":"Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis","volume":"74","author":"Han","year":"2018","journal-title":"Eur Urol"}],"container-title":["Radiography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078817425002470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078817425002470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:49:06Z","timestamp":1767109746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078817425002470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"alternative-id":["S1078817425002470"],"URL":"https:\/\/doi.org\/10.1016\/j.radi.2025.103103","relation":{},"ISSN":["1078-8174"],"issn-type":[{"value":"1078-8174","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate cancer detection with [99mTc]Tc-HYNIC-iPSMA SPECT: The Australian experience","name":"articletitle","label":"Article Title"},{"value":"Radiography","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radi.2025.103103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of The College of Radiographers.","name":"copyright","label":"Copyright"}],"article-number":"103103"}}